Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

Clinical trial NCT05783882 · UNKNOWN

Trial details

NCT number: NCT05783882
Sponsor: Biocad
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable or Metastatic Melanoma

Start date: 2022-02-01
Primary completion: 2023-06-01
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.